Cell Therapies is excited to announce the opening of its new cell and gene therapy GMP manufacturing facilities.
As Australia’s only biomedical manufacturing facility where CAR T-cells and other “living” cancer therapies can be made at a commercial scale, this expansion increases capacity to support high throughput manufacture of clinical trial and commercial cell and gene therapy products for Australian patients and the Asia Pacific market.
The facility expansion includes three large-scale high-throughput GMP manufacturing suites suitable for supply of late-phase clinical trial and commercial products with a production capacity of up to 2,000 patient doses per year.
